SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

MSI NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

NOVARTIS: Click to view the issuer\'s details

Last update : 28/01/2011  >View issuer details

2018.05.17 | 15:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer - HTML (w)

2018.05.16 | 07:00 | Periodic information / Internal Control & Corporate Governance

English version HTML (w) Mail

puce Novartis announces changes to the Executive Committee - HTML (w)

2018.05.16 | 07:00 | Periodic information / Internal Control & Corporate Governance

German version HTML (w) Mail

puce Novartis kündigt Veränderungen in der Geschäftsleitung an - HTML (w)

2018.05.15 | 22:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Novartis successfully completes acquisition of AveXis, Inc. - HTML (w)

2018.05.15 | 06:45 | Public offerings / Statement of purchases / sales

English version HTML (w) Mail

puce Novartis completes tender offer for all outstanding shares of AveXis, Inc. - HTML (w)

2018.05.07 | 07:15 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally - HTML (w)

2018.05.02 | 22:05 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab - HTML (w)

2018.05.01 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Novartis provides update on proposed acquisition of AveXis - HTML (w)

2018.04.30 | 22:10 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1066